Medical Device and Diagnostics
News & Jobs
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  

Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile


Allergan Inc. 

2525 Dupont Drive

Irvine  California  92612  U.S.A.
Phone: 714-246-4500 Fax: n/a


View Clinical Trials from BioPharm Insight

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have approximately 11,100 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. For the year ending 2012, our total product net sales totaled $5.5 billion, a 10 percent increase over 2011. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate more than six decades of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to:

 Key Statistics

Ownership: Public

Web Site: Allergan Inc.
Employees: 11,100
Symbol: AGN



Elan Pharmaceuticals 

CeNes Pharmaceuticals (U.S.) 

PanVera LLC 

Pharmagene Laboratories Limited  Phase ZERO(TM) products and services.

ACADIA Pharmaceuticals, Inc.  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

ACADIA Pharmaceuticals, Inc.  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

ACADIA Pharmaceuticals, Inc.  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

 Company News
Allergan Inc. (AGN) Announces Quarterly Conference Call 4/7/2014 6:57:23 AM    More...
John A. Moran Eye Center’s Voyant Biotherapeutics, LLC Enters Into Exclusive R&D Collaboration Agreement With Allergan Inc. (AGN) 2/21/2014 9:02:31 AM    More...
Former Allergan Inc. (AGN) Marketing Executive Gregory F. Brooks Joins NeuroSigma, Inc. As Senior VP And Chief Commercial Officer 1/27/2014 9:33:22 AM    More...
Actavis (ACT) Comments On Notification To Allergan Inc. (AGN) Of Submission Of Application For Restasis® 1/23/2014 10:51:48 AM    More...
Allergan Inc. (AGN) Axes Undisclosed Amount Of Staffers At California Facility 1/14/2014 8:37:14 AM    More...
Allergan Inc. (AGN) Announces Quarterly Conference Call 1/10/2014 7:05:24 AM    More...
Allergan Inc. (AGN) Accused Of Paying Kickbacks To Spur Eye Drug Sales 12/19/2013 7:33:00 AM    More...
Apollo Endosurgery, Inc. Completes Acquisition of Allergan Inc. (AGN)'s Obesity Intervention Division 12/3/2013 11:14:41 AM    More...
Allergan Inc. (AGN) Agrees to Sell Obesity Unit to Apollo Endosurgery, Inc. for up to $110 Million 10/29/2013 7:45:44 AM    More...
Allergan Inc. (AGN) Reports Third Quarter 2013 Operating Results 10/29/2013 7:17:28 AM    More...